The vote is effectively pre-determined by the 85.3% support agreement. Monitor the closing conditions, particularly NYSE Amex listing approval and the effectiveness of the registration statement. Post-closing, watch for the Zoar shareholder's control and the potential for further dilution or related-party transactions.
Price Chart
Executive Summary
Impact BioMedical Inc. is seeking stockholder approval for a business combination with Zoar Limited, a pharmaceutical company. Existing Impact stockholders will receive approximately 4.80% of the combined entity's shares, representing massive dilution from 100% ownership. The Zoar shareholder will receive approximately 93.32% of the combined entity. The board unanimously recommends approval, supported by a fairness opinion from Corporate Valuation Advisors, Inc. and a voting agreement with holders of 85.3% of Impact shares.
Key Financial Metrics
Key Facts
- Existing Impact stockholders will receive approximately 4.80% of PubCo shares, down from 100% ownership of Impact.
- Zoar shareholder will receive approximately 93.32% of PubCo shares (167,976,000 shares).
- Impact stockholders as of the record date (October 13, 2026) will vote on the business combination on November 13, 2026.
- Supporting shareholders holding 85.3% of outstanding Impact shares have agreed to vote in favor via a Voting and Support Agreement.
- The Impact Board unanimously recommends approval, based in part on a fairness opinion from Corporate Valuation Advisors, Inc.
- Impact must have net cash of at least $10,000 and net debt of $0 at closing.
- The Zoar shareholder will control a majority of voting power post-combination, making PubCo a controlled company.
- Zoar HK has a repayment agreement with Peridot Capital for approximately $8.09 million in outstanding debt, secured by a pledge of PubCo shares.
- Impact's CEO, Frank D. Heuszel, will receive 22,000 PubCo shares as compensation.
- DSS, Inc. will receive 228,000 PubCo shares under the Transition Arrangement Agreement.
Financial Impact
Existing Impact stockholders face massive dilution from 100% to approximately 4.80% ownership of the combined entity. The Zoar shareholder receives 93.32% of the combined entity. No per-share price or total deal value is stated.
Risk Factors
- Massive dilution for existing Impact stockholders, who will own only 4.80% of the combined entity.
- Zoar shareholder will control over 93% of voting power, limiting minority stockholder influence.
- Zoar HK has outstanding debt of approximately $8.09 million to Peridot Capital, secured by a pledge of PubCo shares.
- The business combination is subject to numerous closing conditions, including NYSE Amex listing approval.
- Potential regulatory risks related to operations in Hong Kong and PRC government actions.
- The fairness opinion relies on a Zoar valuation of $877.6 million, which may not be realized.
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFM14A Filing (Primary) | 0001493152-26-048594 |
| Document: formdefm14a.htm | 0001493152-26-048594 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | DEFM14A | $3.40 | awaiting T+60 | awaiting T+60 | $3.55 (−4.41%) |
Apr 29, 2026 25w ago | 144 | $0.6800 $0.4320 | ▲ +36.47% | ▲ +39.58% | $3.55 (−422.06%) |
Apr 3, 2026 29w ago | Press Release | $0.6400 $0.4840 | ▲ +24.38% | ▲ +37.84% | $3.55 (−454.69%) |
Mar 23, 2026 31w ago | Insider Cluster | $0.6470 $0.5770 | ▲ +10.82% | ▲ +23.88% | $3.55 (−448.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers